4.35  0 (0%)		02-06 16:00
Open: 4.36 High: 4.45 Volume: 20,592		Pre. Close: 4.35 Low: 4.31 Market Cap: 46(M)

Short term
Mid term
Targets	6-month :	5.59	1-year :	6.07
Resists	First :	4.78	Second :	5.19
Pivot price	4.53
Supports	First :	4.12	Second :	3.43
MAs	MA(5) :	4.33	MA(20) :	4.61
	MA(100) :	3.36	MA(250) :	2.76
MACD	MACD :	0	Signal :	0.1
%K %D	K(14,3) :	24.3	D(3) :	20.2
RSI	RSI(14): 50.3
52-week	High :	6.19	Low :	1.33

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NRXS ] has closed above bottom band by 27.0%. Bollinger Bands are 20.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.45 - 4.48	4.48 - 4.49
Low:	4.26 - 4.28	4.28 - 4.3
Close:	4.31 - 4.35	4.35 - 4.38

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Fri, 19 Dec 2025
Why NeurAxis Stock Climbed 15% - StocksToTrade

Fri, 19 Dec 2025
NeurAxis Stock Surges: Evaluating The Market Impact - timothysykes.com

Mon, 01 Dec 2025
NeurAxis Secures Veterans Affairs Federal Supply Schedule - GlobeNewswire

Tue, 11 Nov 2025
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues - GlobeNewswire

Sun, 26 Oct 2025
NRXS Stock Falters Amid Market Headwinds and Investor Uncertainty - StocksToTrade

Fri, 24 Oct 2025
Neuraxis stock rises after FDA clearance for abdominal pain treatment - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.